|
|||
 |
|||
|
|
| News |
 |
|
| Top Stories | |
|
|
| Health News | |
|
|
|
|
|
|
|
| Yeast Infection |
 |
|
| What Is Yeast | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Strong alliance to fight fungal infections ntercell AG (VSE: ICLL) today announced that the joint project to develop protective treatments against fungal infections was awarded an EU-grant. Intercell is coordinating a European consortium of three academic and commercial partners within the "CanVac" project. The project aims at developing a vaccine and/or a monoclonal antibody-based therapy against infections caused by the pathogenic fungus Candida albicans. CanVac was one of 41 selected projects among 125 applications submitted for the first two EuroTransBio transnational calls of the European Commission and is eligible to receive funds of EUR 1.5 m. The project is scheduled to run for three years and builds on the expertise of leading scientists and biotech companies in Austria and Germany. Together with the Christian Doppler Research Association (CDG), Intercell AG is also supporting the newly established Christian Doppler Laboratory (CDL) in Infection Biology "PathoFUN". PathoFUN is located at the Max F. Perutz Laboratories, a joint venture of the University of Vienna and the Medical University of Vienna, Campus Vienna Biocenter. The CDL is headed by the renowned expert in fungal pathogenesis, Prof. Karl Kuchler. PathoFunwill focus on genomic approaches to understand fungal virulence and on developing vaccines and/or monoclonal antibody-based therapies against infections caused by fungal pathogens such as Candida and Aspergillus species. ...continued
|
|
||
|
|||
|
|||
|
|||
